OAM
CLDX icon

Oxford Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Oxford Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,453
Closed -$355K – 307
2024
Q1 		$355K Buy
+8,453
New +$347K 0.37% 86
2018
Q3 		– Sell
-23,004
Closed -$173K – 1713
2018
Q2 		$173K Sell
23,004
-12,254
-35% -$164K ﹤0.01% 1601
2018
Q1 		$1.23M Buy
35,258
+5,694
+19% +$221K 0.03% 837
2017
Q4 		$1.3M Buy
29,564
+26,715
+938% +$1.14M 0.03% 802
2017
Q3 		$122K Buy
+2,849
New +$107K ﹤0.01% 1466
2016
Q4 		– Sell
-24,189
Closed -$1.47M – 780
2016
Q3 		$1.47M Buy
+24,189
New +$1.51M 0.05% 452
2016
Q1 		– Sell
-36,581
Closed -$8.7M – 814
2015
Q4 		$8.7M Buy
36,581
+29,680
+430% +$6.47M 0.21% 90
2015
Q3 		$1.09M Buy
+6,901
New +$1.95M 0.03% 395
2014
Q2 		– Sell
-5,415
Closed -$1.44M – 704
2014
Q1 		$1.44M Buy
5,415
+2,749
+103% +$1.05M 0.04% 416
2013
Q4 		$968K Buy
+2,666
New +$1.03M 0.02% 521
2013
Q3 		– Sell
-22,849
Closed -$5.35M – 808
2013
Q2 		$5.35M Buy
+22,849
New +$4.5M 0.14% 223

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oxford Asset Management's CLDX Position: Q2 2024 in Review

Oxford Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 8,453 shares — an estimated $355K sold.

Oxford Asset Management first reported a position in CLDX in Q2 2013 and held it in 11 quarters. The position peaked at $8.7M in Q4 2015. 182 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Oxford Asset Management reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Oxford Asset Management sold 8,453 Celldex Therapeutics shares in Q2 2024, an estimated $355K.
  • Oxford Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 11 quarters.
  • Oxford Asset Management's Celldex Therapeutics position peaked at $8.7M in Q4 2015.
  • 182 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Oxford Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.